Cantor Fitzgerald Reiterates Overweight on Avidity Biosciences, Maintains $96 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Eric Schmidt has reiterated an Overweight rating on Avidity Biosciences (NASDAQ:RNA) and maintained a price target of $96.
September 18, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating for Avidity Biosciences, maintaining a $96 price target, indicating confidence in the company's future performance.
The reiteration of an Overweight rating and a high price target by a reputable analyst suggests positive sentiment and potential upside for Avidity Biosciences' stock. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100